(19)
(11) EP 4 565 281 A1

(12)

(43) Date of publication:
11.06.2025 Bulletin 2025/24

(21) Application number: 23750999.7

(22) Date of filing: 31.07.2023
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61P 35/00(2006.01)
C07K 7/64(2006.01)
A61K 47/64(2017.01)
A61K 39/44(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/6889; A61K 47/6851; A61P 35/00; C07K 16/32; C07K 2317/24; C07K 16/2863; C07K 16/22; C07K 2319/33; A61K 39/44; C07K 7/08; A61K 47/64; A61K 47/68037
(86) International application number:
PCT/EP2023/071199
(87) International publication number:
WO 2024/028282 (08.02.2024 Gazette 2024/06)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 01.08.2022 EP 22382746

(71) Applicants:
  • Gate2Brain, S.L.
    08028 Barcelona (ES)
  • Universitat de Barcelona
    08028 Barcelona (ES)
  • Fundació Institut de Recerca Biomèdica (IRB Barcelona)
    08028 Barcelona (ES)

(72) Inventors:
  • SÁNCHEZ NAVARRO, Macarena
    08028 Barcelona (ES)
  • TEIXIDÓ TURÀ, Meritxell
    08028 Barcelona (ES)
  • GIRALT LLEDÓ, Ernest
    08028 Barcelona (ES)

(74) Representative: ZBM Patents - Zea, Barlocci & Markvardsen 
Rambla de Catalunya, 123
08008 Barcelona
08008 Barcelona (ES)

   


(54) SITE-SPECIFIC MODIFICATION BY A BBB-SHUTTLE OF ANTIBODY-BASED ENTITIES FOR CROSSING THE BLOOD-BRAIN BARRIER